Cover Image
市場調查報告書

ediPoint:全球核影像診斷市場(PET·SPECT設備)--全球市場的分析與預測

MediPoint: Nuclear Imaging - EU Analysis and Market Forecasts

出版商 GlobalData 商品編碼 321241
出版日期 內容資訊 英文 270 Pages
訂單完成後即時交付
價格
Back to Top
ediPoint:全球核影像診斷市場(PET·SPECT設備)--全球市場的分析與預測 MediPoint: Nuclear Imaging - EU Analysis and Market Forecasts
出版日期: 2014年12月31日 內容資訊: 英文 270 Pages
簡介

隨著世界各國醫療改革的發展,降低醫療費支出的壓力漸增,核子醫學攝影診斷技術市場也受到莫大的壓力及影響。隨著既有的正子斷層造影(PET)技術及單光子電腦斷層掃描(SPECT)技術的成熟化,在其與CT(電腦斷層攝影)技術和MRI(核磁共振成像)技術組合產品直線普及下,PET·SPECT專用設備有縮小的趨勢。就不同地區來看,美國雖是全球最大市場,日本、中國市場今後也可望急速成長。

本報告提供全球的核子醫學攝影診斷(PET·SPECT設備等)相關之市場分析,提供您疾病概要和市場結構,目前未滿足需求,主要的推動及阻礙市場要素,今後的市場機會,現在臨床實驗中的主要產品,全球整體及主要10個國家的市場趨勢(過去3年的實際成果值和今後7年的預測值),各類型產品的詳細趨勢,主要企業簡介等調查。

第1章 目錄

第2章 簡介

第3章 產業概要

  • 放射性影像技術
    • 正子輻射斷層攝影(PET)
    • 單光子射出電腦斷層掃描(SPECT)
    • 平面顯像
    • 混合型影像診斷法
  • 核子醫學攝影技術臨床現場的用途
    • 癌症
    • 心臟病
    • 神經症
    • 感染疾病及發炎
  • 核子醫學攝影診斷技術的優點·缺點
  • 市場進入
    • 產品的生命週期
    • 購買意願決策
    • 設備租賃
    • 透過PET/核磁共振攝影交換PET/CT
  • 醫療費給付(全球整體及主要10個國家份)
  • 治療趨勢(計10個國家份)
  • 法規上的課題/回收
  • 企業合併·收購(M&A)波及主要的聯盟
  • 經濟影響(美國·歐洲)

第4章 未滿足需求

  • 概要
  • 改善新技術的醫療費給付
  • 缺乏強制力的臨床指南
  • 患者的舒適性及方便
  • 減少放射線暴露量
  • 改善掃描儀的性能
  • 改善影像處理軟體
  • 混合型影像處理上的人力風險的擴大
  • 新放射性示蹤劑的需求
  • 改善設計流程的臨床性輸入

第5章 市場機會分析

  • 更便宜簡單的核子醫學影像設備
  • 開發中國家的SPECT/CT
  • 遠距放射線醫學服務需求的增加

第6章 市場推動因素及障礙

  • 推動因素:老年人及患病人數的增加
  • 推動因素:醫生認識度的提高
  • 推動因素:國防醫療
  • 推動因素:患者的認識
  • 推動因素:任意詢問
  • 推動因素:新成像劑
  • 推動因素:癌症診斷檢驗的需求擴大
  • 推動因素:搭配診斷實驗
  • 障礙:競爭產品的有效性研究
  • 障礙:醫療費給付法案
  • 障礙:發展中國家市場上的核子醫學攝影診斷的需求擴大
  • 障礙:為了減少無用的影像診斷,保險公司的遊說活動
  • 障礙:EMR保險調查對象者的擴大
  • 障礙:有效性標準的使用增加
  • 障礙:減少無用次序的診療指南
  • 障礙:影像設備的認證
  • 障礙:核醫學技術的損失
  • 障礙:設備·試劑的高成本性
  • 障礙:放射性醫藥品的成本·供給方面的困難性
  • 障礙:醫療設備的物品稅
  • 障礙:醫院的整合

第7章 競爭評估

  • 概要
  • PET專用設備
    • 概要
    • 產品簡介
    • SWOT分析
  • PET/CT設備
  • PET/核磁共振造影系統
  • SPECT專用設備
  • SPECT/CT設備
  • PET/超音波及SPECT/超音波設備

第8章 開發中產品的評估

  • 概要
  • 發展階段的開發中產品
  • 產品簡介(全11產品)

第9章 關注的臨床試驗

  • 概要
  • 臨床實驗簡介

第10章 現在及未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • DDD-Diagnostic
    • Digirad
    • GE Healthcare
    • GVI Medical Devices
    • Mediso Medical Imaging Systems
    • NeuroLogica
    • Neusoft Medical Systems
    • NuCare Medical Systems
    • Oncovision
    • Philips Healthcare
    • 島津製作所
    • Siemens Healthcare
    • SurgicEye
    • 東芝MedicalSystems
    • 其他的企業

第11章 市場展望

  • 企業市場佔有率分析(全球整體及主要10個國家份)
  • 市場部門別組合比例
    • SPECT及SPECT/CT
    • PET,PET/CT及PET/核磁共振攝影
  • 各地區
    • 全球概要
    • 美國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
    • 日本
    • 巴西
    • 中國
    • 印度

第12章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME1131CFR

This report examines how new technologies can emerge in the face of economic pressures that may affect the demand for nuclear imaging, and how healthcare reforms are impacting nuclear medicine. The advent of hybrid imaging has enabled PET/CT imaging to undergo explosive growth. However, this has been at the cost of an increased demand on struggling healthcare budgets. PET and SPECT imaging are well established techniques within nuclear imaging, and are the main focus of this report PET imaging uses Positron Emitting radioactive tracers with a short half life, to image metabolically active organs PET combined with CT allows precise anatomical imaging of the body, identifying diseased areas depending upon the tracer used PET/CT is most often used for cancer diagnosis PET/MRI is a new technique that was introduced to reduce patient exposure to radiation PET only systems are now generally considered obsolete, due to the superior imaging quality of PET/CT

An early diagnosis of disease is the foundation of increasing survival rates. Single-photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging are diagnostic imaging techniques that are widely used in a variety of disease areas including oncology, cardiovascular disease, bone disease, and infectious disease. This report provides an analysis of the nuclear imaging market, with a particular focus on SPECT and PET imaging and hybrid modalities within the 5EU (France, Germany, Italy, Spain, and UK).

Scope

  • An overview of Nuclear Imaging, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized EU Nuclear Imaging market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020.
  • Investigation of current and future market competition for Nuclear Imaging.
  • Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
  • Competitor assessment including device approval analysis and device sales forecasts.
  • Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
  • Analysis of unmet needs within the market and opportunities for future players.
  • Technology trends evaluation to assess strength of pipeline.
  • An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
  • Company profiles including business description, financial overview and SWOT analysis.
  • Coverage of key market players.
  • Strategic assessment of the Nuclear Imaging sector through market impact analysis, future market scenario and company analysis.
  • Direct quotes from Key Opinion Leaders (KOL) as well as doctors

Reasons to buy

  • Understand the trends shaping and driving EU Nuclear Imaging market.
  • Realize device preferences of physicians who have performed the tests already.
  • Access market sizing, forecasts and quantified growth opportunities in EU Nuclear Imaging market through 2018.
  • Quantify candidate patient populations to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
  • Perform benchmarking analysis of growth opportunities against currently marketed products.
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
  • What's the next big thing in EU Nuclear Imaging market landscape? Identify, understand and capitalize.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Industry Overview

  • 3.1. Nuclear Imaging Techniques
    • 3.1.1. Positron Emission Tomography
    • 3.1.2. Single-Photon Emission Computed Tomography
    • 3.1.3. Planar Scintigraphy
    • 3.1.4. Hybrid Imaging
  • 3.2. Clinical Applications of Nuclear Imaging Technology
    • 3.2.1. Cancer
    • 3.2.2. Cardiology
    • 3.2.3. Neurology
    • 3.2.4. Infection and Inflammation
  • 3.3. Advantages and Disadvantages of Nuclear Imaging Technologies
  • 3.4. Market Access
    • 3.4.1. Product Life Cycle
    • 3.4.2. Purchasing Decisions
    • 3.4.3. Equipment Leasing
    • 3.4.4. Replacement of PET/CT by PET/MRI
  • 3.5. Reimbursement
    • 3.5.1. Overview
    • 3.5.2. France
    • 3.5.3. Germany
    • 3.5.4. Italy
    • 3.5.5. Spain
    • 3.5.6. UK
  • 3.6. Procedure Trends
    • 3.6.1. France
    • 3.6.2. Germany
    • 3.6.3. Italy
    • 3.6.4. Spain
    • 3.6.5. UK
  • 3.7. Regulatory Issues/Recalls
  • 3.8. M&As and Key Partnerships
  • 3.9. Economic Impact

4. Unmet Needs

  • 4.1. Overview
  • 4.2. Improved Reimbursement for New Techniques
  • 4.3. Lack of Binding Clinical Guidelines
  • 4.4. Patient Comfort and Convenience
  • 4.5. Reducing Radiation Exposure
  • 4.6. Improved Scanner Performance
  • 4.7. Image Processing Software Improvements
  • 4.8. Increased Risk of Artifacts in Hybrid Images
  • 4.9. Demand for New Radiotracers
  • 4.10. Improved Clinical Input into the Design Process

5. Market Opportunity Analysis

  • 5.1. Cheaper, Simpler Nuclear Imaging Devices
  • 5.2. SPECT/CT in Developing Countries
  • 5.3. Increased Demand for Teleradiology Services

6. Market Drivers and Barriers

  • 6.1. Driver: Aging Population and Increasing Disease Prevalence
  • 6.2. Driver: Referring Physician Awareness
  • 6.3. Driver: Defensive medicine
  • 6.4. Driver: Patient Awareness
  • 6.5. Driver: Self-Referral
  • 6.6. Driver: New Imaging Agents
  • 6.7. Driver: Increasing Demand for Cancer Diagnostic Tests
  • 6.8. Driver: Companion Diagnostic Testing
  • 6.9. Barrier: Comparative Effectiveness Research
  • 6.10. Barrier: Reimbursement Legislation
  • 6.11. Barrier: Increasing Demand for Nuclear Imaging in Developing Markets
  • 6.12. Barrier: Insurance Company Lobbying to Reduce Unnecessary Imaging
  • 6.13. Barrier: Greater Payer Scrutiny of EMRs
  • 6.14. Barrier: Increased Use of Appropriateness Criteria
  • 6.15. Barrier: Practice Guidelines to Reduce Unnecessary Procedures
  • 6.16. Barrier: Imaging Facility Accreditation
  • 6.17. Barrier: Loss of Nuclear Medicine Skills
  • 6.18. Barrier: High Cost of Instruments and Reagents
  • 6.19. Barrier: Radiopharmaceutical Cost and Supply Difficulties
  • 6.20. Barrier: Hospital Consolidation

7. Competitive Assessment

  • 7.1. Overview
  • 7.2. Dedicated PET Systems
    • 7.2.1. Overview
    • 7.2.2. Product Profile
    • 7.2.3. SWOT Analysis
  • 7.3. PET/CT Systems
    • 7.3.1. Overview
    • 7.3.2. Product Profiles
    • 7.3.3. SWOT Analysis
  • 7.4. PET/MRI Systems
    • 7.4.1. Overview
    • 7.4.2. Product Profile
    • 7.4.3. SWOT Analysis
  • 7.5. Dedicated SPECT Systems
    • 7.5.1. Overview
    • 7.5.2. Product Profile
    • 7.5.3. SWOT Analysis
  • 7.6. SPECT/CT Systems
    • 7.6.1. Overview
    • 7.6.2. Product Profile
    • 7.6.3. SWOT Analysis
  • 7.7. PET/Ultrasound and SPECT/Ultrasound Systems
    • 7.7.1. Overview
    • 7.7.2. Product Profile
    • 7.7.3. SWOT Analysis

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Pipeline by Phases in Development
  • 8.3. Product Profiles
    • 8.3.1. Brain Biosciences CerePET
    • 8.3.2. ECORAD Dual Modality Imager
    • 8.3.3. FMI Technologies ScintiStar PET/CT
    • 8.3.4. IntraMedical Imaging Marginator Beta Camera
    • 8.3.5. INSERT SPECT/MRI
    • 8.3.6. Nucare/Zecotek Photonics New Generation PET Scanning Device
    • 8.3.7. Philips Healthcare PET Alpha Ring Detector
    • 8.3.8. Photo Diagnostic Systems NeuroPET/CT
    • 8.3.9. SynchroPET Breast PET/MRI
    • 8.3.10. SynchroPET Wrist Scanner
    • 8.3.11. SurgicEye SPECT Hybrid

9. Clinical Trials to Watch

  • 9.1. Overview
  • 9.2. Clinical Trial Profiles

10. Current and Future Players

  • 10.1. Overview
  • 10.2. Trends in Corporate Strategy
  • 10.3. Company Profiles
    • 10.3.1. DDD-Diagnostic
    • 10.3.2. Digirad
    • 10.3.3. GE Healthcare
    • 10.3.4. GVI Medical Devices
    • 10.3.5. Mediso Medical Imaging Systems
    • 10.3.6. NeuroLogica
    • 10.3.7. Neusoft Medical Systems
    • 10.3.8. NuCare Medical Systems
    • 10.3.9. Oncovision
    • 10.3.10. Philips Healthcare
    • 10.3.11. Shimadzu
    • 10.3.12. Siemens Healthcare
    • 10.3.13. SurgicEye
    • 10.3.14. Toshiba Medical
    • 10.3.15. Other Companies

11. Market Outlooks

  • 11.1. Company Market Share Analysis
    • 11.1.1. Overview
    • 11.1.2. France
    • 11.1.3. Germany
    • 11.1.4. Italy
    • 11.1.5. Spain
    • 11.1.6. UK
  • 11.2. Market Segment Share
    • 11.2.1. SPECT & SPECT/CT
    • 11.2.2. PET, PET/CT & PET/MRI
  • 11.3. By Geography
    • 11.3.1. Overview
    • 11.3.2. France
    • 11.3.3. Germany
    • 11.3.4. Italy
    • 11.3.5. Spain
    • 11.3.6. UK

12. Appendix

  • 12.1. Abbreviations
  • 12.2. Bibliography
  • 12.3. Methodology
    • 12.3.1. Overview
    • 12.3.2. Coverage
    • 12.3.3. Secondary Research
  • 12.4. Physicians and Specialists Included in This Study
  • 12.5. Primary Research
    • 12.5.1. Primary Research - Key Opinion Leader Interviews
    • 12.5.2. Expert Panel Validation
    • 12.5.3. Stakeholder Survey
  • 12.6. Forecasting Methodology
  • 12.7. About the Authors
    • 12.7.1. Andrew Thompson, PhD, Senior Analyst
    • 12.7.2. Priya Radhakrishnan, MBA, Director, Medical Devices
    • 12.7.3. Bonnie Bain, PhD, Global Head of Healthcare
  • 12.8. About GlobalData
  • 12.9. Disclaimer

List of Tables

  • Table 1: Applications of Nuclear Imaging
  • Table 2: FDG-PET Diagnostic Accuracy for Specific Cancers
  • Table 3: Potential Clinical Benefits of Hybrid Nuclear Imaging in Cardiology
  • Table 4: Applications of PET Imaging in Non-Cancer Neurology
  • Table 5: Applications of SPECT Imaging in Non-Cancer Neurology
  • Table 6: Characteristics of SPECT, PET, Ultrasound, CT, and MRI
  • Table 7: The Age of Canada's Hospital-Based Medical Technology Inventories, Relative to ECCREI Rules, 2009
  • Table 8: Nuclear Imaging Trends in France, 2012-2020
  • Table 9: Nuclear Imaging Trends in Germany, 2012-2020
  • Table 10: Nuclear Imaging Trends in Italy, 2012-2020
  • Table 11: Nuclear Imaging Trends in Spain, 2012-2020
  • Table 12: Nuclear Imaging Trends in UK, 2012-2020
  • Table 13: Recent Device Recalls in the Nuclear Imaging Market
  • Table 14: Recent Key Events in the Nuclear Imaging Market
  • Table 15: Nuclear Imaging Market Drivers and Barriers
  • Table 16: Duplicate Diagnostic Test Incidence in France, Germany, UK, and US
  • Table 17: Dedicated PET Scanners
  • Table 18: Dedicated PET SWOT Analysis
  • Table 19: PET/CT Scanners
  • Table 20: PET/CT SWOT Analysis
  • Table 21: PET/MRI Systems
  • Table 22: PET/MRI SWOT Analysis
  • Table 23: Dedicated SPECT Systems
  • Table 24: Dedicated SPECT SWOT Analysis
  • Table 25: SPECT/CT Systems
  • Table 26: SPECT/CT SWOT Analysis
  • Table 27: SPECT-Ultrasound Systems
  • Table 28: SPECT/Ultrasound SWOT Analysis
  • Table 29: Nuclear Imaging Pipeline, 2014
  • Table 30: CerePET SWOT Analysis
  • Table 31: ECORAD Dual Modality Imager SWOT Analysis
  • Table 32: ScintiStar PET/CT SWOT Analysis
  • Table 33: Marginator SWOT Analysis
  • Table 34: INSERT SPECT-MRI SWOT Analysis
  • Table 35: Nucare/Zecotek Photonics New Generation PET Scanning Device SWOT Analysis
  • Table 36: PET Alpha Ring Detector
  • Table 37: NeuroPET/CT Scanner SWOT Analysis
  • Table 38: SynchroPET Breast PET/MRI SWOT Analysis
  • Table 39: SynchroPET Wrist Scanner
  • Table 40: SurgicEye SPECT/Ultrasound device SWOT Analysis
  • Table 41: Key Clinical Trials
  • Table 42: Company Profile - DDD-Diagnostic
  • Table 43: DDD-Diagnostic SWOT Analysis
  • Table 44: Company Profile - Digirad
  • Table 45: Digirad SWOT Analysis
  • Table 46: Company Profile - GE Healthcare
  • Table 47: GE Healthcare Product Portfolio
  • Table 48: GE Healthcare SWOT Analysis
  • Table 49: Company Profile - GVI Medical Devices
  • Table 50: GVI Medical Devices SWOT Analysis
  • Table 51: Company Profile - Mediso Medical Imaging Systems
  • Table 52: Mediso Medical Imaging Systems SWOT Analysis
  • Table 53: Company Profile - Neurologica
  • Table 54: Neurologica SWOT Analysis
  • Table 55: Company Profile - Neusoft Medical Systems
  • Table 56: Neusoft Medical Systems SWOT Analysis
  • Table 57: Company Profile - NuCare Medical Systems
  • Table 58: Nucare Medical Systems SWOT Analysis
  • Table 59: Company Profile - Oncovision
  • Table 60: Oncovision SWOT Analysis
  • Table 61: Company Profile - Philips Healthcare
  • Table 62: Philips Healthcare SWOT Analysis
  • Table 63: Company Profile - Shimadzu
  • Table 64: Shimadzu SWOT Analysis
  • Table 65: Company Profile - Siemens Healthcare
  • Table 66: Siemens Healthcare SWOT Analysis
  • Table 67: Company Profile - SurgicEye
  • Table 68: SurgicEye SWOT Analysis
  • Table 69: Company Profile - Toshiba Medical
  • Table 70: Toshiba Medical SWOT Analysis
  • Table 71: Other Companies in the Nuclear Imaging Market, 2014
  • Table 72: EU5 Market Value Forecast by Market Segment for SPECT & SPECT/CT (2012-2020)
  • Table 73: EU5 Market Value Forecast by Market Segment for PET, PET/CT & PET/MRI (2012-2020)
  • Table 74: EU5 Sales of PET and SPECT Imaging Systems, 2012-2020
  • Table 75: France Market Value Forecast by Market Sub segment (2012-2020)
  • Table 76: Germany Market Value Forecast by Market Sub segment (2012-2020)
  • Table 77: Italy Market Value Forecast by Market Sub-segment (2012-2020)
  • Table 78: Spain Market Value Forecast by Market Sub-segment (2012-2020)
  • Table 79: UK Market Value Forecast by Market Sub-segment (2012-2020)
  • Table 80: Primary Research Summary
  • Table 81: Primary Research Participants Affiliation

List of Figures

  • Figure 1: Cyclotron Distribution in 10 Countries
  • Figure 2: Localization of Tumor in Chest Cavity by PET, CT, and PET/CT
  • Figure 3: Mutually Beneficial Effects of PET/MRI Imaging
  • Figure 4: Nuclear Imaging Trends in France, 2012-2020
  • Figure 5: Nuclear Imaging Trends in Germany, 2012-2020
  • Figure 6: Nuclear Imaging Trends in Italy, 2012-2020
  • Figure 7: Nuclear Imaging Trends in Spain, 2012-2020
  • Figure 8: Nuclear Imaging Trends in UK, 2012-2020
  • Figure 9: Imaging Utilization Rates (Number of Outpatient Visits with MRI/CT per 1,000 Persons), by Year in the US
  • Figure 10: EU5 Company Market Shares for Nuclear Imaging Equipment (2012)
  • Figure 11: France Company Market Shares for Nuclear Imaging Equipment (2012)
  • Figure 12: Germany Company Market Shares for Nuclear Imaging Equipment (2012)
  • Figure 13: Italy Company Market Shares for Nuclear Imaging Equipment (2012)
  • Figure 14: Spain Company Market Shares for Nuclear Imaging Equipment (2012)
  • Figure 15: UK Company Market Shares for Nuclear Imaging Equipment (2012)
  • Figure 16: EU5 Market Value Forecast by Market Segment for SPECT & SPECT/CT (2012-2020)
  • Figure 17: EU5 Market Value Forecast by Market Segment for PET, PET/CT, and PET/MRI (2012-2020)
  • Figure 18: EU5 Sales of PET and SPECT Imaging Systems, 2012-2020
  • Figure 19: France Market Value Forecast by Market Subsegment (2012-2020)
  • Figure 20: Germany Market Value Forecast by Market Sub segment (2012-2020)
  • Figure 21: Italy Market Value Forecast by Market Sub segment (2012-2020)
  • Figure 22: Spain Market Value Forecast by Market Sub-segment (2012-2020)
  • Figure 23: UK Market Value Forecast by Market Sub-segment (2012-2020)
  • Figure 24: Primary Research Summary
  • Figure 25: Primary Research Participants Affiliation
Back to Top